Development of a Novel Imaging Agent for Determining Albumin Uptake in Solid Tumors

Overview of attention for article published in Nuclear Medicine and Molecular Imaging, February 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#1 of 209)
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (87th percentile)

Mentioned by

news: 15 news outlets

twitter: 1 X user

Citations

dimensions_citation: 5 Dimensions

Readers on

mendeley: 10 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 32 news stories from 15 outlets.

CytRx Corporation Reports First Quarter 2019 Financial Results

Ariva, 15 May 2019

PR Newswire LOS ANGELES, May 15, 2019 LOS ANGELES, May 15, 2019 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a…

CytRx Corporation Reports First Quarter 2019 Financial Results

Biospace, 15 May 2019

LOS ANGELES, May 15, 2019 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development…

CytRx Corporation Reports First Quarter 2019 Financial Results

WFMJ, 15 May 2019

SOURCE CytRx Corporation Out-licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High…

CytRx Corporation Reports First Quarter 2019 Financial Results

Kuam, 15 May 2019

SOURCE CytRx Corporation Out-licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High…

CytRx Corporation Reports First Quarter 2019 Financial Results

WBOC 16, 15 May 2019

SOURCE CytRx Corporation Out-licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High…

CytRx Corporation Reports First Quarter 2019 Financial Results

2 News, 15 May 2019

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today…

CytRx Corporation Reports First Quarter 2019 Financial Results

Ticker Tech, 15 May 2019

/PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology…

CytRx Corporation Reports First Quarter 2019 Financial Results

Benzinga, 15 May 2019

/ / -- CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today…

CytRx Corporation Reports First Quarter 2019 Financial Results

Yahoo! Finance USA, 15 May 2019

Out-licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High Unmet NeedCytRx Stands to…

CytRx Corporation Reports First Quarter 2019 Financial Results

PR Newswire, 15 May 2019

Out-licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High Unmet Need LOS ANGELES…

CytRx Corporation Reports First Quarter 2019 Financial Results

NASDAQ, 15 May 2019

Out-licensed Assets Aldoxorubicin and Arimoclomol Rapidly Advancing into Multiple Indications of High Unmet Need CytRx Stands…

CytRx Corporation Reports 2018 Financial Results

Kuam, 29 Mar 2019

SOURCE CytRx Corporation LADR™ Assets Well Aligned with Current Oncology Trends, Including Need for Improved Drugs and…

CytRx Corporation Reports 2018 Financial Results

WFMJ, 29 Mar 2019

SOURCE CytRx Corporation LADR™ Assets Well Aligned with Current Oncology Trends, Including Need for Improved Drugs and…

CytRx Corporation Reports 2018 Financial Results

CBS8, 29 Mar 2019

SOURCE CytRx Corporation LADR™ Assets Well Aligned with Current Oncology Trends, Including Need for Improved Drugs and…

CytRx Corporation Reports 2018 Financial Results

WBOC 16, 29 Mar 2019

SOURCE CytRx Corporation LADR™ Assets Well Aligned with Current Oncology Trends, Including Need for Improved Drugs and…

CytRx Corporation Reports 2018 Financial Results

2 News, 29 Mar 2019

CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology, today…

CytRx Corporation Reports 2018 Financial Results

News 9, 29 Mar 2019

SOURCE CytRx Corporation LADR™ Assets Well Aligned with Current Oncology Trends, Including Need for Improved Drugs and…

CytRx Corporation Reports 2018 Financial Results

Biospace, 29 Mar 2019

LOS ANGELES, March 29, 2019 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development…

CytRx Corporation Reports 2018 Financial Results

PharmiWeb, 29 Mar 2019

/PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology…

CytRx Corporation Reports 2018 Financial Results

Morning Star, 29 Mar 2019

/PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology…

CytRx Corporation Reports 2018 Financial Results

Ariva, 29 Mar 2019

PR Newswire LOS ANGELES, March 29, 2019 LOS ANGELES, March 29, 2019 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a…

CytRx Corporation Reports 2018 Financial Results

Ticker Tech, 29 Mar 2019

/PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research and development company specializing in oncology…

CytRx Corporation Reports 2018 Financial Results

Benzinga, 29 Mar 2019

/PRNewswire/ -- CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology…

CytRx Corporation Reports 2018 Financial Results

PR Newswire, 29 Mar 2019

LADR™ Assets Well Aligned with Current Oncology Trends, Including Need for Improved Drugs and Potential for Combination with…

CytRx Corporation Reports 2018 Financial Results

NASDAQ, 29 Mar 2019

LADR™ Assets Well Aligned with Current Oncology Trends, Including Need for Improved Drugs and Potential for Combination with…

CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems

Kuam, 12 Mar 2019

SOURCE CytRx Corporation Novel Imaging Agent Would Enable Oncologists to Predict Which Patients Will Respond to Albumin-Binding…

CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems

WBOC 16, 12 Mar 2019

SOURCE CytRx Corporation Novel Imaging Agent Would Enable Oncologists to Predict Which Patients Will Respond to Albumin-Binding…

CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems

CBS8, 12 Mar 2019

SOURCE CytRx Corporation Novel Imaging Agent Would Enable Oncologists to Predict Which Patients Will Respond to Albumin-Binding…

CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems

WFMJ, 12 Mar 2019

SOURCE CytRx Corporation Novel Imaging Agent Would Enable Oncologists to Predict Which Patients Will Respond to Albumin-Binding…

CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems

Ticker Tech, 12 Mar 2019

/PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology…

CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems

Ariva, 12 Mar 2019

PR Newswire LOS ANGELES, March 12, 2019 LOS ANGELES, March 12, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a…

CytRx Corporation's Subsidiary, Centurion BioPharma Corporation's Albumin Companion Diagnostic (ACDx), Could Be The First To Personalize Medicine For Albumin-Based Drug Delivery Systems

PR Newswire, 12 Mar 2019

Novel Imaging Agent Would Enable Oncologists to Predict Which Patients Will Respond to Albumin-Binding Cytotoxic Treatment LOS…